Two case reports involving therapeutic monoclonal anti-CD47 (Hu5F9-G4), it's effect on compatibility testing and subsequent selection of components for transfusion
Authors
Reyland, LDwight, M
Bullock, T
Latham, T
Lord, K
Wardle, A
Palmer, D
Eggington, J
Callaghan, T
Seals, Deborah
Kulkarni, Samar
Affiliation
NHS Blood and Transplant-Filton, Red Cell Immunohaematology Laboratory, Bristol, UKIssue Date
2020
Metadata
Show full item recordCitation
Reyland L, Dwight M, Bullock T, Latham T, Lord K, Wardle A, et al. Two case reports involving therapeutic monoclonal anti-CD47 (Hu5F9-G4), it's effect on compatibility testing and subsequent selection of components for transfusion. Transfus Med. 2020.Journal
Transfusion MedicineDOI
10.1111/tme.12664PubMed ID
31914482Additional Links
https://dx.doi.org/10.1111/tme.12664Type
ArticleLanguage
enae974a485f413a2113503eed53cd6c53
10.1111/tme.12664
Scopus Count
Collections
Related articles
- Transfusion management in the era of magrolimab (Hu5F9-G4), an anti-CD47 monoclonal antibody therapy.
- Authors: Singh N, Staves J, Storry JR, Dinoso J, Renard C, Doshi P, Johnson LDS, Westhoff CM, Murphy MF
- Issue date: 2023 Dec
- The effects of monoclonal anti-CD47 on RBCs, compatibility testing, and transfusion requirements in refractory acute myeloid leukemia.
- Authors: Brierley CK, Staves J, Roberts C, Johnson H, Vyas P, Goodnough LT, Murphy MF
- Issue date: 2019 Jul
- How do transfusion services manage patients taking therapies such as anti-CD38 and anti-CD47 known to interfere with red blood cell compatibility testing?
- Authors: Murphy MF, Rajbhandary S, Carayiannis S, Cohn CS
- Issue date: 2024 Jul
- Pre-Clinical Development of a Humanized Anti-CD47 Antibody with Anti-Cancer Therapeutic Potential.
- Authors: Liu J, Wang L, Zhao F, Tseng S, Narayanan C, Shura L, Willingham S, Howard M, Prohaska S, Volkmer J, Chao M, Weissman IL, Majeti R
- Issue date: 2015
- Disrupting the CD47-SIRPα anti-phagocytic axis by a humanized anti-CD47 antibody is an efficacious treatment for malignant pediatric brain tumors.
- Authors: Gholamin S, Mitra SS, Feroze AH, Liu J, Kahn SA, Zhang M, Esparza R, Richard C, Ramaswamy V, Remke M, Volkmer AK, Willingham S, Ponnuswami A, McCarty A, Lovelace P, Storm TA, Schubert S, Hutter G, Narayanan C, Chu P, Raabe EH, Harsh G 4th, Taylor MD, Monje M, Cho YJ, Majeti R, Volkmer JP, Fisher PG, Grant G, Steinberg GK, Vogel H, Edwards M, Weissman IL, Cheshier SH
- Issue date: 2017 Mar 15